Page 2

Biond Biologics forms corporate bonds to raise $17m
Celgene has taken part in a Harel Insurance Finance-led series B round that will fund the progress of Biond's lead immuno-oncology drug into clinical trials.
Corporate venturing deal net: 7-11 January 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Keros constructs $23m series B round
Keros Therapeutics will use the proceeds from the Partners Healthcare and Medison Pharma-backed round to push its rare muscle disease drugs into clinical trials.
Horizn Studios carries away series B funding
Vorwerk Ventures returned to reinvest in the smart luggage developer as part of an $11.4m round that also featured Project A and Milano Investment Partners.
Frequency tunes into $42m
Proceeds from the Alexandria Real Estate Equities-backed series B round will advance the company's development of progenitor cell-related medicines for hearing loss.
Exscientia sends for $26m
Celgene and Evotec both invested in Exscientia, as the automated drug discovery services provider added Roche to its roster of development partners.
Baicells connects to Qualcomm in series B-plus round
The Century Internet-backed broadband network technology provider has raised $14.6m in a round led by Qualcomm Ventures.
Boom Supersonic smashes series B with $100m
Ctrip and Japan Airlines-backed supersonic aircraft developer Boom has completed a $100m series B round that brought its total funding to more than $140m.
Oculis eyes Nan Fung to boost series B
Investors including Nan Fung and Tekla Capital have increased the ophthalmic treatment developer's series B round to $35.9m, following a Novartis-led tranche a year ago.
Jinda Nano produces series B round
Xiamen C&D has taken part in a $29.1m round for Jinda Nano Tech that will fuel the antibacterial product maker's research into nanotechnology.

test reg